Key facts
- Egenesis’s last known valuation is $330.0M.
- It has raised $454.0M across 5 recorded rounds; the latest was Later Stage VC ($125.0M) in Feb 2021.
- Notable investors include Khosla Ventures, Lux Capital, Alexandria Venture Investments, ARCH Venture Partners, Catalio Capital Management — 37 tracked in total.
- Egenesis has filed 5 Form Ds with the SEC since 2016, most recently Feb 2024 ($25.4M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 37 names
- ·Watchlist + deal alerts for Egenesis
Funding rounds
5 roundsAbout Egenesis
Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs. The company offers a genome-engineering platform that inactivates porcine retroviruses, inserts human genes, and edits multiple immune-rejection pathways to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases, enabling patients with organ failure to access transplantable tissues and organs with improved compatibility and safety.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2015
- Employees
- 135
- Website
- egenesisbio.com/
- Ownership
- Privately Held (backing)
Egenesis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Egenesis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Egenesis in its N-PORT filings yet. We sweep new filings monthly.